CPA CPA - Absci Corp Chief Officer
| ABSI Stock | USD 4.32 0.01 0.23% |
Insider
CPA CPA is Chief Officer of Absci Corp
| Age | 65 |
| Address | 18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683 |
| Phone | 360 949 1041 |
| Web | https://www.absci.com |
Absci Corp Management Efficiency
The company has return on total asset (ROA) of (0.2398) % which means that it has lost $0.2398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4224) %, meaning that it created substantial loss on money invested by shareholders. Absci Corp's management efficiency ratios could be used to measure how well Absci Corp manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.62. The current Return On Capital Employed is estimated to decrease to -0.48. As of now, Absci Corp's Total Current Assets are increasing as compared to previous years. The Absci Corp's current Fixed Asset Turnover is estimated to increase to 0.23, while Non Current Assets Total are projected to decrease to under 92.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexis AM | Relay Therapeutics | 52 | |
| Shafique MD | Recursion Pharmaceuticals | 53 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Margo Mosley | Exscientia Ltd ADR | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Blake Borgeson | Recursion Pharmaceuticals | 42 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Derek Jantz | Precision BioSciences | 48 | |
| FRSE DPHIL | Exscientia Ltd ADR | 51 | |
| Thomas Catinazzo | Relay Therapeutics | 47 | |
| Cindy Hayashi | Caribou Biosciences | N/A | |
| MSc MBA | Inozyme Pharma | 52 | |
| John Kelly | Precision BioSciences | 57 | |
| Andy Porter | Relay Therapeutics | N/A | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Benjamin MS | Recursion Pharmaceuticals | 41 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.24 |
Absci Corp Leadership Team
Elected by the shareholders, the Absci Corp's board of directors comprises two types of representatives: Absci Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Absci. The board's role is to monitor Absci Corp's management team and ensure that shareholders' interests are well served. Absci Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Absci Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sean McClain, CEO, Founder | ||
| CPA CPA, Chief Officer | ||
| Christian MBA, Senior Creation | ||
| Shelby JD, Chief Officer | ||
| Karin Wierinck, Chief Officer | ||
| Sarah JD, Chief Sec | ||
| Jens Plassmeier, Senior Technology | ||
| Todd CPA, Senior Officer | ||
| Melissa Patterson, Chief Staff | ||
| Jonathan MS, VP Informatics | ||
| Zachariah Jonasson, Chief CFO | ||
| Alexander CPA, VP Relations | ||
| DVM MBA, Senior Strategy | ||
| Denise Dettore, Chief Officer | ||
| Andreas Busch, Chief Officer | ||
| Thomas JD, VP Property | ||
| Amaro TaylorWeiner, Chief Officer | ||
| Wen Sha, Chief Staff | ||
| Jack Gold, Chief Officer |
Absci Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Absci Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (21.04) % | ||||
| Current Valuation | 357.51 M | ||||
| Shares Outstanding | 113.56 M | ||||
| Shares Owned By Insiders | 20.31 % | ||||
| Shares Owned By Institutions | 60.74 % | ||||
| Number Of Shares Shorted | 12.08 M | ||||
| Price To Book | 2.21 X | ||||
| Price To Sales | 150.94 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Absci Stock
When determining whether Absci Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Absci Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Absci Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Absci Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Absci Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Absci Stock please use our How to Invest in Absci Corp guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Absci Corp. If investors know Absci will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Absci Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 0.033 | Quarterly Revenue Growth (0.62) | Return On Assets (0.24) | Return On Equity (0.42) |
The market value of Absci Corp is measured differently than its book value, which is the value of Absci that is recorded on the company's balance sheet. Investors also form their own opinion of Absci Corp's value that differs from its market value or its book value, called intrinsic value, which is Absci Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Absci Corp's market value can be influenced by many factors that don't directly affect Absci Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Absci Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Absci Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Absci Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.